Skip to main navigation

Investors

Press Releases

Press Releases

Year

June 5, 2023

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

SAN CARLOS, Calif. , June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced

May 9, 2023

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

SAN CARLOS, Calif. , May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first

March 6, 2023

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN CARLOS, Calif. , March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth

(Common Stock)

May 27, 2023 3:29 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Toolkit

Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information

About
Science
Clinical
- Overview
- Lirentelimab in Mast Cell and Eosinophil Driven Diseases
Patients
- Allakos Commitment
- EGID Resources
Investors
Careers
- Working at Allakos
- Open Positions
Contact

About
Science
Clinical
- Overview
- Lirentelimab in Mast Cell and Eosinophil Driven Diseases
Patients
- Allakos Commitment
- EGID Resources
Investors
Careers
- Working at Allakos
- Open Positions
Contact

© Allakos Inc. All rights reservedWebsite Design: Hane Chow, Inc.

Privacy and Cookie Policy
Terms of Use